Press Releases

 

Financial

  Date Title and Summary View
Aug 8, 2016
LAWRENCEVILLE, N.J., Aug. 08, 2016 (GLOBE NEWSWIRE) -- Celsion Corporation (NASDAQ:CLSN) announced today that the Company will host a conference call to discuss financial results for the quarter and six-month period ended June 30, 2016 and provide an update on its development programs for ThermoDox®, its proprietary heat-activated liposomal ...
Jun 13, 2016
LAWRENCEVILLE, N.J., June 13, 2016 (GLOBE NEWSWIRE) -- Celsion Corporation (the "Company") (NASDAQ:CLSN) today announced that it has entered into a definitive agreement with a single healthcare dedicated institutional investor to purchase an aggregate of approximately $6 million of shares of common stock, or pre-funded warrants in lieu thereof, i...
May 16, 2016
LAWRENCEVILLE, N.J., May 16, 2016 /PRNewswire/ -- Celsion Corporation (NASDAQ: CLSN), an oncology drug development company, today announced financial results for the quarter ended March 31, 2016 and provided an update on its development programs for ThermoDox®, its proprietary heat-activated liposomal encapsulation of doxorubicin and GEN-1, an...
May 9, 2016
LAWRENCEVILLE, N.J., May 9, 2016 /PRNewswire/ -- Celsion Corporation (NASDAQ: CLSN) announced today that the Company will host a conference call to discuss financial results for the quarter ended March 31, 2016 and provide an update on its development programs for ThermoDox®, its proprietary heat-activated liposomal encapsulation of doxorubici...
Mar 30, 2016
LAWRENCEVILLE, N.J., March 30, 2016 /PRNewswire/ -- Celsion Corporation (NASDAQ: CLSN), an oncology drug development company, today announced financial results for the year ended December 31, 2015 and provided an update on its development programs for ThermoDox®, its proprietary heat-activated liposomal encapsulation of doxorubicin and GEN-1, ...
Mar 23, 2016
LAWRENCEVILLE, N.J., March 23, 2016 /PRNewswire/ -- Celsion Corporation (NASDAQ: CLSN) announced today that the Company will host a conference call to discuss year-end 2015 financial results and provide an update on its development programs for ThermoDox®, its proprietary heat-activated liposomal encapsulation of doxorubicin and GEN-1, an IL-1...
Nov 24, 2015
LAWRENCEVILLE, N.J., Nov. 24, 2015 /PRNewswire/ -- Celsion Corporation (NASDAQ: CLSN), a fully-integrated oncology company focused on the development of a portfolio of innovative cancer treatments, including directed chemotherapies, immunotherapies and RNA- or DNA-based therapies for the treatment of cancer and other difficult-to-treat diseases, to...
Nov 5, 2015
LAWRENCEVILLE, N.J., Nov. 5, 2015 /PRNewswire/ -- Celsion Corporation (NASDAQ: CLSN), an oncology drug development company, today announced financial results for the quarter ended September 30, 2015 and provided an update on its development programs, including ThermoDox®, its proprietary heat-activated liposomal encapsulation of doxorubicin, a...
Oct 29, 2015
LAWRENCEVILLE, N.J., Oct. 29, 2015 /PRNewswire/ -- Celsion Corporation (NASDAQ: CLSN) announced today that the Company will host a conference call to discuss its third quarter 2015 financial results and provide an update on its development programs for ThermoDox®, its proprietary heat-activated liposomal encapsulation of doxorubicin, and two n...
Oct 15, 2015
LAWRENCEVILLE, N.J., Oct. 15, 2015 /PRNewswire/ -- Celsion Corporation (NASDAQ: CLSN) today announced that it will host a Research and Development (R&D) Day for investors and analysts on Tuesday, October 27, 2015.  The event is scheduled to take place from 4:00 to 6:00 p.m. Eastern Time in New York City, and will be simultaneously streamed as a web...
Page: FirstPrevious
3
... NextLast
= add release to Briefcase
Share This